Suhuang antitussive capsule in the treatment of bronchial asthma--a multi-center, randomized, double-blind, placebo-controlled clinical study

Phase 4

• Conditions: Bronchial Asthma

• Registration Number: ITMCTR2200005511
• Lead Sponsor: Shanghai General Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) Outpatients with chronic persistent of asthma who meet the typical asthma diagnostic criteria in the 2020 edition of the Guidelines for the Prevention and Treatment of Bronchial Asthma;
(2) The severity is graded as mild or moderate, and the ACT score is =19 points;
(3) Age from 18 to 60 years old;
(4) Sign the informed consent form.
Those who meet all the above criteria at the same time can be included in the study.

Exclusion Criteria

(1) Combined use of compound methoxyphenamine capsules, codeine tablets, codeine oral solution, compound pseudoephedrine hydrochloride oral solution, tabellae dextpomethorphani hydrobromiditablets, compound licorice tablets, Jizhi syrup, Shedan Chuanbei loquat ointment, Xianzhuli Oral Liquid, Qutanling Oral Liquid, Qutan Zhike capsules, Fei Li Ke Mixture, Xuanfei Zhisou Mixture and other medicines containing anti-cough ingredients, or Maxing Zhike Tablets, Gejie Dingchuan Pills and other Chinese traditional medicines containing ephedra ingredients within 2 weeks;
(2) Patients with a history of arrhythmia, coronary atherosclerotic heart disease, hypertension or hyperthyroidism, and poor control;
(3) Patients with severe heart, liver, kidney, brain, mental, or neurological diseases;
(4) Allergic to drugs known in this study;
(5) Pregnant or lactating women or those planning pregnancy;
(6) Those who have participated in or are participating in other clinical trials within 28 days;
(7) Those who are deemed unsuitable to participate in this trial by the researcher.
Those who meet any of the above criterion cannot be included in this study.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ACT score;

Secondary Outcome Measures

Name	Time	Method
ung function;AQLQ score;Exploratory index;Safety index;LCQ score;Clinical symptom score;